Impact Factor 2021: 3.041 (@Clarivate Analytics)
5-Year Impact Factor: 2.776 (@Clarivate Analytics)
Immediacy Index: 0.927
  • Users Online: 1106
  • Print this page
  • Email this page
This article has been cited by
1Ivermectin for preventing and treating COVID-19
Maria Popp,Stefanie Reis,Selina Schießer,Renate Ilona Hausinger,Miriam Stegemann,Maria-Inti Metzendorf,Peter Kranke,Patrick Meybohm,Nicole Skoetz,Stephanie Weibel
Cochrane Database of Systematic Reviews.2022;2022(6)
[DOI]
2Meta-Analyses Do Not Establish Improved Mortality With Ivermectin Use in COVID-19
Steven G. Rothrock,Kurt D. Weber,Philip A. Giordano,Mitchell D. Barneck
American Journal of Therapeutics.2022;29(2)e237
[DOI]
3Dose-Dependent Ivermectin Effect on COVID-19 Polymerase Chain Reaction Status
Nirmeen Sabry,Yasser Fouad,Mohamed AbdAllah,Ahmed Cordie,Gamal Esmat
American Journal of Therapeutics.2022;Publish Ahead of Print(2)e237
[DOI]
4Efficacy of COVID-19 Treatments: A Bayesian Network Meta-Analysis of Randomized Controlled Trials
Chenyang Zhang,Huaqing Jin,Yi Feng Wen,Guosheng Yin
Frontiers in Public Health.2021;9(2)e237
[DOI]
5The lesson of ivermectin: meta-analyses based on summary data alone are inherently unreliable
Jack M. Lawrence,Gideon Meyerowitz-Katz,James A. J. Heathers,Nicholas J. L. Brown,Kyle A. Sheldrick
Nature Medicine.2021;27(11)1853
[DOI]
6Ivermectin for COVID-19: Addressing Potential Bias and Medical Fraud
Andrew Hill,Manya Mirchandani,Victoria Pilkington
Open Forum Infectious Diseases.2022;9(2)1853
[DOI]
7A Survey for Predictors of Mortality among COVID-19 Patients: A Retrospective Study from Iran
arezoo monfared,mohammad taghi moghadamnia,Samad Karkhah,saman maroufizadeh,Mohammad Asadian Rad,Jalal kheirkhah,fatemeh jafaraghayee
Jorjani Biomedicine Journal.2021;9(4)13
[DOI]
8Re: “Commentary” by Rothrock et al. “Meta-Analyses Did Not Establish Improved Mortality With Ivermectin Use in COVID-19”
Andrew Bryant,Theresa A. Lawrie,Edmund J. Fordham,Scott Mitchell
American Journal of Therapeutics.2022;29(2)e233
[DOI]
9Identification and Development of Therapeutics for COVID-19
Halie M. Rando,Nils Wellhausen,Soumita Ghosh,Alexandra J. Lee,Anna Ada Dattoli,Fengling Hu,James Brian Byrd,Diane N. Rafizadeh,Ronan Lordan,Yanjun Qi,Yuchen Sun,Christian Brueffer,Jeffrey M. Field,Marouen Ben Guebila,Nafisa M. Jadavji,Ashwin N. Skelly,Bharath Ramsundar,Jinhui Wang,Rishi Raj Goel,YoSon Park,Simina M. Boca,Anthony Gitter,Casey S. Greene,Jack A. Gilbert
mSystems.2021;6(6)e233
[DOI]
10Comparative effectiveness of pharmacological interventions on mortality and the average length of hospital stay of patients with COVID-19: a systematic review and meta-analysis of randomized controlled trials
Abolfazl Akbari,Mahya Razmi,Alireza Sedaghat,Seyyed Mohammad Matin Alavi Dana,Mahdi Amiri,Ali Mohammad Halvani,Soroush Yazdani,Sajad Sahab-Negah
Expert Review of Anti-infective Therapy.2022;20(4)585
[DOI]
11Meta-Analyses Do Not Establish Improved Mortality With Ivermectin Use in COVID-19
Steven G. Rothrock,Kurt D. Weber,Philip A. Giordano,Mitchell D. Barneck
American Journal of Therapeutics.2022;29(1)e87
[DOI]
12Bayesian Hypothesis Testing and Hierarchical Modeling of Ivermectin Effectiveness
Martin Neil,Norman Fenton
American Journal of Therapeutics.2021;28(5)e576
[DOI]
13Ivermectin under scrutiny: a systematic review and meta-analysis of efficacy and possible sources of controversies in COVID-19 patients
Arman Shafiee,Mohammad Mobin Teymouri Athar,Omid Kohandel Gargari,Kyana Jafarabady,Sepehr Siahvoshi,Sayed-Hamidreza Mozhgani
Virology Journal.2022;19(1)e576
[DOI]